English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
Vinmec's Innovations Spotlighted at Global CSR & ESG Summit 2024
May 09, 2024 05:04 HKT
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08, 2024 09:00 HKT
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT
Avance Clinical은 4월 23일부터 25일까지 보스턴에서 열리는 세계 고아약 학회에서 임상 우수성을 선보입니다
Apr 22, 2024 08:00 HKT
Avance Clinical 在4月23日至25日波士顿世界孤儿药物会议上展示临床突出成绩
Apr 20, 2024 18:00 HKT
Avance Clinical 在4月23日至25日波士頓世界孤兒藥物會議上展示臨床突出成績
Apr 20, 2024 18:00 HKT
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
Apr 19, 2024 16:00 HKT
Avance Clinical은 세계 백신 대회에서 최신 백신 임상시험 뉴스를 공유합니다. 이 중에는 HIV-1 연구도 포함됩니다
Mar 29, 2024 06:42 HKT
Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞,包括HIV-1研究
Mar 29, 2024 06:33 HKT
Avance Clinical将在世界疫苗大会上分享最新的疫苗临床试验新闻,包括HIV-1研究
Mar 29, 2024 06:22 HKT
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT
亿胜生物公布2023年度业绩,收入增长29.5%,利润增长22.1%
Mar 18, 2024 21:32 HKT
億勝生物公布2023年度業績,收入增長29.5%,利潤增長22.1%
Mar 18, 2024 21:31 HKT
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Mar 18, 2024 21:30 HKT
Avance Clinical首席执行官谈论了“美国生物技术行业的绿色新苗”和一份新的CRO报告
Feb 28, 2024 17:00 HKT
Avance Clinical執行長談論了「美國生物技術產業的綠色新苗」和一份新的CRO報告
Feb 28, 2024 17:00 HKT
Avance Clinical CEO는 US 바이오 기술 부문에 대한 "초록색 나무순"과 새로운 CRO 보고서에 대해 SCRIP와 대화했습니다
Feb 28, 2024 17:00 HKT
LYC Healthcare Reports Strong Q3 FY2024 Results of RM36.0 Million
Feb 28, 2024 09:34 HKT
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
Feb 28, 2024 08:00 HKT
최신 분석에 따르면 미국의 바이오테크 기업 중 65%가 적절한 CRO파트너를 식별하는 데 어려움을 겪고 있습니다
Jan 17, 2024 09:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: